Latest Breaking News On - சிறப்பு பிராண்டுகள் - Page 3 : comparemela.com
National Association of Manufacturers Selects Mallinckrodt for Two Prestigious Manufacturing Leadership Awards
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Mallinckrodt Announces 2021 Advancing Extracorporeal Photopheresis Immunomodulation Investigator Award
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DUBLIN, March 10, 2021 /PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKKQ) ( Mallinckrodt or the Company ) today announced that it has reached agreement with an ad hoc group of first lien term lenders holding approximately $1.3 billion of its outstanding First Lien Term Loans (the First Lien Term Loan Lenders ) to support the Company s previously announced restructuring support agreement ( RSA ). The agreement, which is based on providing new term loans financing to replace the First Lien Term Loans, resolves the open dispute between the Company and the First Lien Term Loan Lenders as to how such Lenders are to be treated under the restructuring plan and serves to extend near-term debt maturities.
New England Journal of Medicine.
Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration (FDA) or Health Canada.
As previously announced, the Phase 3 CONFIRM study met its primary endpoint of Verified HRS Reversal, which is defined as renal function improvement, avoidance of dialysis and short-term survival. The main objective of the CONFIRM study was to assess the efficacy and safety of terlipressin, together with albumin, versus placebo in adults in the U.S. and Canada with cirrhosis and HRS-1. The trial met three of the four pre-specified secondary endpoints of the study including HRS reversal,
Share this article
NEW YORK, Feb. 24, 2021 /PRNewswire/
Amid the COVID-19 pandemic, the global addiction therapeutics market registered a YOY growth of 5.7% in 2020 and the market is estimated to expand at a CAGR of almost 6% during the forecast period. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the market in optimistic, probable, and pessimistic forecast scenarios.
Addictions Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025
For the Right Perspective & Competitive Insights –
The 120-page report analyzes the addiction therapeutics market by type (alcohol addiction therapeutics, tobacco addiction therapeutics, and drug addiction therapeutics) and geography (North America, Europe, APAC, and ROW). The report offers competitive intelligence about market leaders, key industry opportunities, trends, and threats impacting the growth of the market. Also, the report includes information on marketing, brand, strategy
vimarsana © 2020. All Rights Reserved.